TOI ONCOLOGY INSTITUTE INC (THE)

The American Journal of Managed Care® and The Oncology Institute to Co-Host Symposium for Value-Based Cancer Care

The American Journal of Managed Care® and The Oncology Institute to Co-Host Symposium for Value-Based Cancer Care

CERRITOS, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Today, the Oncology Institute, Inc. and its affiliates (NASDAQ: TOI) shared its partnership with the American Journal of Managed Care® (AJMC) to co-host a symposium focused on value-based cancer care. The event will take place on October 24, 2024, in Miami, Florida, as part of AJMC’s Institute for Value-Based Medicine (IVBM).

The IVBM serves as a premier forum where leading expert faculty share their insights and experiences in implementing value-based care for oncology and population health stakeholders. Attendees can expect dynamic panel discussions featuring a diverse range of healthcare professionals, including physicians, practice administrators, and payors, addressing key learnings and emerging opportunities in the field.

The symposium will be chaired by Dr. Daniel Virnich, Chief Executive Officer of The Oncology Institute. Key TOI executives moderating panels include Chief Medical Officer, Dr. Yale Podnos, Chief Development Officer Jordan McInerney, and Vice President, Ray Parzik.

For more information and to register for this event, please contact . 

About The Oncology Institute

Founded in 2007, TOI is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of over 1.8 million patients including clinical trials, transfusions, and other services traditionally associated with the most advanced care delivery organizations. With over 120 employed clinicians and more than 700 teammates in over 70 clinic locations, TOI is changing oncology for the better. For more information visit . 

About the American Journal of Managed Care

The American Journal of Managed Care® (AJMC®) is a leader in managed care research, offering actionable insights and peer perspectives through our leading peer-reviewed journals, AJMC®, The American Journal of Accountable Care®, and AJMC®’s Evidence-Based Oncology™. In addition, AJMC® provides commentary and the latest news through other platforms, including , the Managed Care Cast podcast, and best-in-class video content. AJMC® keeps industry leaders on the forefront of health policy by sharing research relevant to industry decision makers. Our digital platform, AJMC.com, distributes health care news to leading stakeholders across a variety of media, including peer-to-peer video interviews, podcasts, conference coverage, interactive resources, and more. Our live events bring together industry thought leaders to exchange insights and perspectives on the evolving health care landscape.

Contacts

Investors at Solebury Strategic Communications



EN
14/10/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ONCOLOGY INSTITUTE INC (THE)

 PRESS RELEASE

The Oncology Institute Reports Fourth Quarter and Full Year 2025 Finan...

The Oncology Institute Reports Fourth Quarter and Full Year 2025 Financial Results and Guidance for 2026 CERRITOS, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its fourth quarter and year ended December 31, 2025. Recent Operational Highlights Cash flow from operations in Q4 2025 was approximately $3.2 million, due to disciplined working capital management and overall increase in gross profit marginConti...

 PRESS RELEASE

The Oncology Institute Announces Fourth Quarter and Full Year 2025 Ear...

The Oncology Institute Announces Fourth Quarter and Full Year 2025 Earnings Release Date and Conference Call CERRITOS, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI)  a pioneer in value-based community oncology care, today announced that the company will release its fourth quarter and full year 2025 financial results on Thursday, March 12, 2026, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time). The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-...

 PRESS RELEASE

The Oncology Institute to Participate in Multiple Healthcare Investor ...

The Oncology Institute to Participate in Multiple Healthcare Investor Conferences in March CERRITOS, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), a pioneer in value-based community oncology care, today announced that members of its executive leadership team will participate in several investor conferences in March. Details for the conferences are as follows: Jefferies Healthcare Services Innovation & Technology SummitPresentation: Monday, March 9, 2026, from 11:30 a.m. to 12:00 p.m. ETLocation: Miami, FLPresenter: Dr. Daniel Virnich, Chief Execut...

 PRESS RELEASE

The Oncology Institute Appoints Kim Tzoumakas to Board of Directors

The Oncology Institute Appoints Kim Tzoumakas to Board of Directors CERRITOS, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced the appointment of Kim Tzoumakas to its Board of Directors, effective February 23, 2026. Ms. Tzoumakas brings more than two decades of executive leadership experience across oncology, pharmacy services and healthcare operations. Notably, she is Chief Executive Officer for VytlOne National Pharmacy Services, and previously held the CEO r...

 PRESS RELEASE

The Oncology Institute Reaffirms 2025 Guidance and Provides Preliminar...

The Oncology Institute Reaffirms 2025 Guidance and Provides Preliminary 2026 Outlook CERRITOS, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based oncology groups in the United States, today reaffirmed 2025 guidance and provided its preliminary 2026 outlook. 2026 Outlook For 2026, TOI anticipates that total revenue will be in the range of $630 million to $650 million, reflecting 28% growth from the midpoint of 2025 and 2026 guidance ranges, and including approximately $150 million of Capitation rev...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch